http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 02 Sep 2026 07:08:17 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Dogwood+Therapeutics%2C+Inc.+%28DWTX%29/27015561.html <p>H.C. Wainwright analyst Sean Lee reiterated a Buy rating and $12.00 price target on Dogwood Therapeutics, Inc. (NASDAQ: DWTX).</p><p>The analyst commented: "During the call, management disclosed that 232 patients have been recruited into the Phase 2b study of Halneuron for the treatment of CINP with the last patient to be randomized this week. They further reaffirmed the fall timing for the topline results, which we now expect between late-October to mid-November. Enrollment into the 12-week open label extension is now at 80+ patients, with 20 patients completing the 12 weeks of treatment. Early terminations from the extension study remain low http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Dogwood+Therapeutics%2C+Inc.+%28DWTX%29/27015561.html Wed, 02 Sep 2026 07:08:17 -0400 DWTX http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html <p align="justify">ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html Mon, 17 Aug 2026 08:30:00 -0400 A.03607790 A.05414222 A.35006980 A.39871067 A.50214881 A.60012009 DWTX O.00793356 O.00982552 O.02092487 O.04708750 O.11263818 O.20147506 O.71961715 http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html <p align="justify">ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html Mon, 17 Aug 2026 08:30:00 -0400 A.03607790 A.05414222 A.35006980 A.39871067 A.50214881 A.60012009 DWTX O.00793356 O.00982552 O.02092487 O.04708750 O.11263818 O.20147506 O.71961715 http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html <p align="justify">ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html Mon, 17 Aug 2026 08:30:00 -0400 A.03607790 A.05414222 A.35006980 A.39871067 A.50214881 A.60012009 DWTX O.00793356 O.00982552 O.02092487 O.04708750 O.11263818 O.20147506 O.71961715 http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html <p align="justify">ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html Mon, 17 Aug 2026 08:30:00 -0400 A.03607790 A.05414222 A.35006980 A.39871067 A.50214881 A.60012009 DWTX O.00793356 O.00982552 O.02092487 O.04708750 O.11263818 O.20147506 O.71961715 http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html <p align="justify">ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html Mon, 17 Aug 2026 08:30:00 -0400 A.03607790 A.05414222 A.35006980 A.39871067 A.50214881 A.60012009 DWTX O.00793356 O.00982552 O.02092487 O.04708750 O.11263818 O.20147506 O.71961715 http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html <p align="justify">ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html Mon, 17 Aug 2026 08:30:00 -0400 A.03607790 A.05414222 A.35006980 A.39871067 A.50214881 A.60012009 DWTX O.00793356 O.00982552 O.02092487 O.04708750 O.11263818 O.20147506 O.71961715 http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html <p align="justify">ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html Mon, 17 Aug 2026 08:30:00 -0400 A.03607790 A.05414222 A.35006980 A.39871067 A.50214881 A.60012009 DWTX O.00793356 O.00982552 O.02092487 O.04708750 O.11263818 O.20147506 O.71961715 http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html <p align="justify">ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html Mon, 17 Aug 2026 08:30:00 -0400 A.03607790 A.05414222 A.35006980 A.39871067 A.50214881 A.60012009 DWTX O.00793356 O.00982552 O.02092487 O.04708750 O.11263818 O.20147506 O.71961715 http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html <p align="justify">ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html Mon, 17 Aug 2026 08:30:00 -0400 A.03607790 A.05414222 A.35006980 A.39871067 A.50214881 A.60012009 DWTX O.00793356 O.00982552 O.02092487 O.04708750 O.11263818 O.20147506 O.71961715 http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html <p align="justify">ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html Mon, 17 Aug 2026 08:30:00 -0400 A.03607790 A.05414222 A.35006980 A.39871067 A.50214881 A.60012009 DWTX O.00793356 O.00982552 O.02092487 O.04708750 O.11263818 O.20147506 O.71961715 http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html <p align="justify">ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html Mon, 17 Aug 2026 08:30:00 -0400 A.03607790 A.05414222 A.35006980 A.39871067 A.50214881 A.60012009 DWTX O.00793356 O.00982552 O.02092487 O.04708750 O.11263818 O.20147506 O.71961715 http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html <p align="justify">ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html Mon, 17 Aug 2026 08:30:00 -0400 A.03607790 A.05414222 A.35006980 A.39871067 A.50214881 A.60012009 DWTX O.00793356 O.00982552 O.02092487 O.04708750 O.11263818 O.20147506 O.71961715 http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html <p align="justify">ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html Mon, 17 Aug 2026 08:30:00 -0400 A.03607790 A.05414222 A.35006980 A.39871067 A.50214881 A.60012009 DWTX O.00793356 O.00982552 O.02092487 O.04708750 O.11263818 O.20147506 O.71961715 http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html <p align="justify">ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic http://www.streetinsider.com/Press+Releases/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html Mon, 17 Aug 2026 08:30:00 -0400 A.03607790 A.05414222 A.35006980 A.39871067 A.50214881 A.60012009 DWTX O.00793356 O.00982552 O.02092487 O.04708750 O.11263818 O.20147506 O.71961715 http://www.streetinsider.com/Globe+Newswire/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html <p align="justify">ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic http://www.streetinsider.com/Globe+Newswire/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html Mon, 17 Aug 2026 08:30:00 -0400 A.03607790 A.05414222 A.35006980 A.39871067 A.50214881 A.60012009 DWTX O.00793356 O.00982552 O.02092487 O.04708750 O.11263818 O.20147506 O.71961715 http://www.streetinsider.com/Globe+Newswire/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html <p align="justify">ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic http://www.streetinsider.com/Globe+Newswire/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html Mon, 17 Aug 2026 08:30:00 -0400 A.03607790 A.05414222 A.35006980 A.39871067 A.50214881 A.60012009 DWTX O.00793356 O.00982552 O.02092487 O.04708750 O.11263818 O.20147506 O.71961715 http://www.streetinsider.com/Globe+Newswire/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html <p align="justify">ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic http://www.streetinsider.com/Globe+Newswire/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html Mon, 17 Aug 2026 08:30:00 -0400 A.03607790 A.05414222 A.35006980 A.39871067 A.50214881 A.60012009 DWTX O.00793356 O.00982552 O.02092487 O.04708750 O.11263818 O.20147506 O.71961715 http://www.streetinsider.com/Globe+Newswire/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html <p align="justify">ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic http://www.streetinsider.com/Globe+Newswire/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html Mon, 17 Aug 2026 08:30:00 -0400 A.03607790 A.05414222 A.35006980 A.39871067 A.50214881 A.60012009 DWTX O.00793356 O.00982552 O.02092487 O.04708750 O.11263818 O.20147506 O.71961715 http://www.streetinsider.com/Globe+Newswire/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html <p align="justify">ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic http://www.streetinsider.com/Globe+Newswire/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html Mon, 17 Aug 2026 08:30:00 -0400 A.03607790 A.05414222 A.35006980 A.39871067 A.50214881 A.60012009 DWTX O.00793356 O.00982552 O.02092487 O.04708750 O.11263818 O.20147506 O.71961715 http://www.streetinsider.com/Globe+Newswire/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html <p align="justify">ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic http://www.streetinsider.com/Globe+Newswire/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html Mon, 17 Aug 2026 08:30:00 -0400 A.03607790 A.05414222 A.35006980 A.39871067 A.50214881 A.60012009 DWTX O.00793356 O.00982552 O.02092487 O.04708750 O.11263818 O.20147506 O.71961715 http://www.streetinsider.com/Globe+Newswire/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html <p align="justify">ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic http://www.streetinsider.com/Globe+Newswire/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html Mon, 17 Aug 2026 08:30:00 -0400 A.03607790 A.05414222 A.35006980 A.39871067 A.50214881 A.60012009 DWTX O.00793356 O.00982552 O.02092487 O.04708750 O.11263818 O.20147506 O.71961715 http://www.streetinsider.com/Globe+Newswire/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html <p align="justify">ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic http://www.streetinsider.com/Globe+Newswire/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html Mon, 17 Aug 2026 08:30:00 -0400 A.03607790 A.05414222 A.35006980 A.39871067 A.50214881 A.60012009 DWTX O.00793356 O.00982552 O.02092487 O.04708750 O.11263818 O.20147506 O.71961715 http://www.streetinsider.com/Globe+Newswire/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html <p align="justify">ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic http://www.streetinsider.com/Globe+Newswire/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html Mon, 17 Aug 2026 08:30:00 -0400 A.03607790 A.05414222 A.35006980 A.39871067 A.50214881 A.60012009 DWTX O.00793356 O.00982552 O.02092487 O.04708750 O.11263818 O.20147506 O.71961715 http://www.streetinsider.com/Globe+Newswire/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html <p align="justify">ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic http://www.streetinsider.com/Globe+Newswire/Dogwood+to+Host+Virtual+KOL+Event+to+Discuss+Halneuron%C2%AE+for+the+Treatment+of+Chemotherapy+Induced+Neuropathic+Pain+on+September+1%2C+2026/26935342.html Mon, 17 Aug 2026 08:30:00 -0400 A.03607790 A.05414222 A.35006980 A.39871067 A.50214881 A.60012009 DWTX O.00793356 O.00982552 O.02092487 O.04708750 O.11263818 O.20147506 O.71961715